Delivering Shareholder Value Presentation (1)

Delivering Shareholder Value Presentation (1)

• 1. Investor Day • 2024 Delivering Shareholder Value Aradhana Sarin, CFO

• 2. Investor Day • 2024 Forward looking statements 2 In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ‘the Group’) provides the following cautionary statement: This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected or targeted revenues, margins, earnings per share or other financial or other measures (including the Financial Ambition Statements described in this presentation). Although the Group believes its expectations and targets are based on reasonable assumptions and has used customary forecasting methodologies used in the pharmaceutical industry and risk-adjusted projections for individual medicines (which take into account the probability of success of individual clinical trials, based on industry-wide data for relevant clinical trials at a similar stage of development), any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group’s control, include, among other things: the risk of failure or delay in delivery of pipeline or launch of new medicines; the risk of failure to meet regulatory or ethical requirements for medicine development or approval; the risk of failures or delays in the quality or execution of the Group’s commercial strategies; the risk of pricing, affordability, access and competitive pressures; the risk of failure to maintain supply of compliant, quality medicines; the risk of illegal trade in the Group’s medicines; the impact of reliance on third-party goods and services; the risk of failure in information technology or cybersecurity; the risk of failure of critical processes; the risk of failure to collect and manage data in line with legal and regulatory requirements and strategic objectives; the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce; the risk of failure to meet regulatory or ethical expectations on environmental impact, including climate change; the risk of the safety and efficacy of marketed medicines being questioned; the risk of adverse outcome of litigation and/or governmental investigations; intellectual property-related risks to the Group’s products; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of failure in financial control or the occurrence of fraud; the risk of unexpected deterioration in the Group’s financial position; the impact that global and/or geopolitical events may have, or continue to have, on these risks, on the Group’s ability to continue to mitigate these risks, and on the Group’s operations, financial results or financial condition There can be no guarantees that the conditions to the closing of the proposed transaction with Fusion will be satisfied on the expected timetable, or at all, or that “FPI-2265” (Ac225-PSMA I&T) or any combination product will receive the necessary regulatory approvals or prove to be commercially successful if approved. There can be no guarantees that the conditions to the closing of the proposed transaction with Amolyt Pharma will be satisfied on the expected timetable, or at all, or that eneboparatide (‘AZP-3601’) will receive the necessary regulatory approvals or prove to be commercially successful if approved. This presentation includes references to new molecular entities and life-cycle management programmes that are being investigated in current or future clinical trials, and as such have not been approved by any regulatory agency. For a list of new molecular entities and indications in development, see pages 7-11 of the Clinical Trials Appendix that accompanied AstraZeneca’s Q1 2024 results. Basis of AstraZeneca ambitions, forecasts and targets AstraZeneca ambitions, forecasts and targets in this presentation (the “Financial Ambition Statements”) are derived from AstraZeneca’s most recent risk-adjusted mid- and long-term plans, adjusted for developments in the business since those plans were finalised. Financial Ambition Statements presented are based on management’s risk-adjusted projections for individual medicines and individual clinical trials. Estimates for these probabilities are based on industry-wide data for relevant clinical trials in the pharmaceutical industry at a similar stage of development adjusted for management's view on the risk profile of the specific asset. The peak year revenue (PYR) potential for individual medicines referred to in this presentation are the maximum estimated Total Revenue to be recognised by AstraZeneca in a single calendar year, during the lifecycle of the medicine, and are based on management’s latest non-risk adjusted forecast estimates. Estimates are based on customary forecasting methodologies used in the pharmaceutical industry. Peak year revenue may occur in different years for each NME depending on trial outcomes, approval label, competition, launch dates and exclusivity periods, amongst other variables. The peak year revenue figures are derived from net sales at nominal values and are not risk-adjusted or time-value discounted. The development of pharmaceutical products has inherent risks given scientific experimentation and there are a range of possible outcomes in clinical results, safety, efficacy and product labelling. Clinical results may not achieve the desired product profile and competitive environment, pricing and reimbursement may have material impact on commercial revenue forecasts. By their nature, forecasts are based on a multiplicity of assumptions and actual performance in future years may vary, significantly and materially, from these assumptions. The Financial Ambition Statements in this presentation are based on Q1 2024 exchange rates; AZ undertakes no obligation to update those statements based on future currency movements

• 3. Investor Day • 2024 Delivering on shareholder value 3 TSR 1 January 2013-17th May 2024. Peer group includes AbbVie, Amgen, Astellas, BMS, Daiichi Sankyo, Eli Lilly, Gilead, GSK, Johnson&Johnson, Merck, Merck KGaA, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi & Takeda. TSR measured in local currency. Source: Datastream. Acronym definitions can be found in Glossary. AstraZeneca has delivered superior shareholder returns since 2013 Index Total shareholder return % 100 150 200 250 300 350 400 450 500 550 600 650 12/31/201211/30/201310/31/2014 9/30/20158/31/20167/31/20176/30/20185/31/20194/30/20203/31/20212/28/20221/31/2023 12/31/2023 AZN FTSE100 Peer median +535% +198% +121%

• 4. Investor Day • 2024 Ambition – $80bn Total Revenue by 2030 and sustained 2030+ growth Note: Ambition to achieve $80bn in Total Revenue by 2030 is risk-adjusted, based on latest long-range plan – see the ‘Forward looking statements’ slide. Medicines and assets listed reflect key contributors to 2030 Total Revenue ambition; however, this list is not exhaustive. Medicines and assets listed in alphabetical order and sorted by therapy area. 1. Amolyt Pharma acquisition remains subject to customary external clearances; all clinical development plans mentioned herein subject to deal closure. Collaboration partners: Daiichi Sankyo (Enhertu, Dato-DXd), Amgen (Tezspire), Ionis (Wainua), Compugen (rilvegostomig), Merck & Co., Inc. (Lynparza). Acronym definitions can be found in Glossary. 2023 2030 $45.8bn IRA impact Loss of Exclusivity Existing portfolio Calquence Enhertu Imfinzi/Imjudo Tagrisso Truqap Airsupra Breztri Fasenra Lokelma Saphnelo Tezspire Wainua Ultomiris Launching key NMEs AZD0120 AZD0486 camizestrant Dato-DXd rilvegostomig saruparib volrustomig AZN ADCs baxdrostat dapa FDCs IVX-A12 tozorakimab efzimfotase alfa eneboparatide1 $80bn ADCs and Radioconjugates Cell therapy and T-cell engagers Gene therapy Next-generation IO bispecifics Weight management and risk factors Beyond 2030 Brilinta Farxiga Lynparza Soliris Illustrative only, not to scale 4 2030 Total Revenue ambition not dependent upon future M&A

• 5. Investor Day • 2024 Strong growth potential 2030+ Multiple NMEs with $5bn+ Peak Year Revenue potential launching by 20301 5 1. Non-risk adjusted Peak Year Revenue opportunities ($bn). Peak revenues could occur beyond 2030. Estimated launch dates are subject to change. 2. Baxdrostat franchise including dapagliflozin combination. 3. includes fixed-dose combinations with balcinrenone and zibotentan. 4. CLDN18.2, B7H4, EGFR/cMET, FRα, GPRC5D, CD123. Acronym definitions can be found in Glossary. Collaboration partners: Daiichi Sankyo (Dato-DXd), Compugen (rilvegostomig). *Includes several medicines with multi-blockbuster potential Dato-DXd TROP2 ADC | breast, lung, other camizestrant ngSERD | breast cancer volrustomig PD-1/CTLA-4 | lung, HNSCC, others rilvegostomig PD-1/TIGIT | lung, BTC, others saruparib PARPi | prostate, others baxdrostat franchise2 ASI | hypertension dapagliflozin FDCs3 SGLT2i/MRM/ETA | cardiorenal NMEs currently in Phase III NMEs currently in Phase I/II AZD0780 oPCSK9 | dyslipidaemia weight management* oGLP-1/FDCs AZD0486 CD19/CD3 | haematology AZN ADCs*,4 multiple | solid tumours, haem AZD0120 (GC012F) BCMA/CD19 | haematology

• 6. Investor Day • 2024 Significant growth in blockbuster portfolio by 2030 6 1. Blockbuster = medicines with in-market Product Sales >$1bn per year. 2. Based on non-risk adjusted 2030 forecast. List shown is not exhaustive. Acronym definitions can be found in Glossary. Collaboration partners: Daiichi Sankyo (Enhertu, Dato-DXd); Merck & Co., Inc. (Lynparza); Compugen (rilvegostomig); Ionis (Wainua). Existing blockbuster medicines1 25+ potential blockbusters by 20302 Dato-DXd camizestrant baxdrostat franchise tozorakimab rilvegostomig IVX-A12 efzimfotase alfa AZN ADCs AZD0120 AZD0486 saruparib volrustomig + zibotentan/ dapagliflozin balcinrenone/ dapagliflozin

• 7. Investor Day • 2024 • Portfolio prioritisation based on scientific merit and riskadjusted NPV • Robust forecasting • Early lifecycle planning • Strategic business development Operational model drives organisation productivity 7 • Rigorous technical reviews • External advisory boards • Biomarker and patient segmentation • Leading operational execution • Annual planning process • Continual optimisation • Incentives aligned to R&D delivery Focus on value creation Smart clinical development Robust process and aligned incentives Acronym definitions can be found in Glossary.

• 8. Investor Day • 2024 Continued focus on cash conversion 8 Acronym definitions can be found in Glossary. Increasing cash generation Improving cash conversion Net cash inflow from operating activities Operating cash flow as % of Total Revenue Vaxzevria impact $m 0 2,000 4,000 6,000 8,000 10,000 12,000 2020 2021 2022 2023

• 9. Investor Day • 2024 Capital allocation priorities remain unchanged 9 1. Net Debt/Adjusted EBITDA as of Q1 2024. Rolling 12m EBITDA adding back the impact of unwind of inventory fair value uplift recognised on acquisition of Alexion of $78m (FY 2023: $114m). Acronym definitions can be found in Glossary. Reinvestment in our business (incl. CapEx) Strong investment-grade credit rating Business development Progressive dividend policy CapEx investment to support revenue growth 1.9x Net Debt/Adjusted EBITDA1 +$0.10 +$0.20 2022 2024 Value-enhancing business development

• 10. Investor Day • 2024 CapEx investments to support future growth 10 Future CapEx – investment to support top-line growth Investing and building capacity to support growth in disruptive categories Cell therapy capacity for ex-US markets ADC manufacturing (Singapore) New R&D/shared hub investments Cell therapy (Rockville, MD, United States) Radiopharmaceuticals supply chain API facility (Dublin, Ireland) Inhaled facility (Qingdao, China) 2024 CapEx investments – building manufacturing capacity Enterprise resourcing planning (SAP S/4 HANA Global) Acronym definitions can be found in Glossary.

• 11. Investor Day • 2024 On track to achieve mid-30s% Core operating margin by 2026 11 COVID-19 medicines included Evusheld and Vaxzevria. Acronym definitions can be found in Glossary. $m % Core SG&A % of Total Revenue to decrease • Greater speciality mix • LCMs leveraging existing commercial model • LOEs enabling resource redeployment • Optimising global footprint Core R&D to remain at low-20s% of Total Revenue 20% 22% 24% 26% 28% 30% 32% 34% 36% 20,000 25,000 30,000 35,000 40,000 45,000 50,000 2020 2021 2022 2023 Total Revenue ex. COVID-19 Covid-19 revenue Core Operating Margin % Core SG&A % Core R&D %

• 12. Investor Day • 2024 Core operating margin beyond 2026 Investment in innovation to drive growth to 2030 and beyond 12 Acronym definitions can be found in Glossary. Beyond 2026, Core operating margin will be influenced by portfolio evolution, and the Company will target at least mid-30s% Core R&D to remain at low-20s% of Total Revenue sustaining scientific leadership into the next decade Investing in innovation to deliver 2030+ growth • Commercial launches in large market opportunities ― Large new potential opportunities in primary care ― Novel combinations and specialty areas ― New indications in core therapeutic areas • Investing in new modalities, technologies and disruptive categories • Global access to innovative medicines

• 13. Investor Day • 2024 AstraZeneca set to deliver continued shareholder value 13 Acronym definitions can be found in Glossary. Therapy Area Leadership Financial Ambitions Scientific Innovation People and Planet • Ambition to launch 20 NMEs by 2030 • 25+ potential blockbusters by 2030 • Leverage depth and breadth of pipeline • Continued growth across geographies • Deliver $80bn in Total Revenue by 2030 • Invest to drive next waves of growth 2030+ • Mid-30s% Core operating margin by 2026 • Beyond 2026 targeting at least mid-30s% Core operating margin • Smart capital allocation priorities • Lead in new technologies and modalities • Leverage combinations in specialty areas • Accelerate innovation globally • Expand access and build health system resilience • Reduce absolute Scope 1 and 2 emissions by 98% by 2026 • Scope 3 emissions by 50% by 2030 • Science led, entrepreneurial culture and exceptional talent

• 14. Investor Day • 2024 Q&A session Anas Younes SVP, GLOBAL HEAD OF HAEMATOLOGY R&D Matt Hellmann VP, HEAD OF CLINICAL GROUP, EARLY DEVELOPMENT ONCOLOGY R&D Aradhana Sarin CFO, ASTRAZENECA Sunil Verma SVP, GLOBAL HEAD OF ONCOLOGY, MEDICAL Ingrid Mayer VP, BREAST AND GYNECOLOGIC CANCERS, R&D Susan Galbraith EVP, ONCOLOGY R&D Rob Chen GLOBAL HEAD OF LYMPHOMA CLINICAL DEVELOPMENT Osama Rahma VP, GLOBAL CLINICAL STRATEGY HEAD, GI CANCER Nina Shah GLOBAL HEAD OF MULTIPLE MYELOMA CLINICAL DEVELOPMENT AND STRATEGY Puja Sapra SVP, BIOLOGICS ENGINEERING AND TARGETED DELIVERY Leora Horn LATE CLINICAL DEVELOPMENT AND GLOBAL CLINICAL STRATEGY LEAD LUNG CANCER Pascal Soriot CEO, ASTRAZENECA Mark Cobbold VP, IO DISCOVERY AND HEAD OF ONCOLOGY CELL THERAPY Cristian Massacesi CHIEF MEDICAL OFFICER AND ONCOLOGY CHIEF DEVELOPMENT OFFICER Dave Fredrickson EVP, ONCOLOGY

• 15. Investor Day • 2024 Summary and Close Pascal Soriot, CEO

• 16. Investor Day • 2024 Concluding remarks 16 AstraZeneca is a unique investment opportunity with a clear path to deliver sustained long-term growth 1 New ambition to deliver $80bn in Total Revenue by 2030, with sustained growth 2030+ 2 3 Global commercial footprint provides substantial growth opportunity for our medicines 4 High value late-stage pipeline: • $20bn potential revenue in 2030 (non-risk adjusted) from 2024/2025 launches and Phase III readouts • Significant number of NMEs $5bn+ PYR expected to launch by 2030 5 Investment in disruptive categories to drive 2030+ growth Note: Ambition to achieve $80bn in Total Revenue by 2030 is risk-adjusted, based on latest long-range plan – see slide 3 for details. non-risk adjusted Peak Year Revenue opportunities ($bn). Peak revenues could occur beyond 2030. Estimated launch dates are subject to change. Acronym definitions can be found in Glossary. Investor Day • 2024 Mid-30s% Core operating margin by 2026. Beyond 2026, Core operating margin will be influenced by portfolio evolution and the Company will target at least mid-30s%

• 17. 17 Investor Day • 2024 Appendix

• 18. 18 Investor Day • 2024 Glossary – 1 of 2 CLL chronic lymphocytic leukaemia cm centimetre CM cardiomyopathy cMET c-mesenchymal epithelial transition factor COPD chronic obstructive pulmonary disease CRwNP chronic rhinosinusitis with nasal polyps CSA-AKI cardiac surgery-associated acute kidney injury ctDNA circulating tumour DNA CTLA4 cytotoxic T-lymphocyte associated protein 4 CTx chemotherapy CV cardiovascular CVRM Cardiovascular, Renal and Metabolism DDR DNA damage response DGF delayed graft function DLBCL diffuse large B-cell lymphoma dnTGFb dominant-negative transforming growth factor-beta dPTEN phosphatase and tensin homolog deficient EBITDA Earnings before interest, tax, depreciation and amortisation EGFR epidermal growth factor receptor eGFR estimated glomerular filtration rate EGPA eosinophilic granulomatosis with polyangiitis EM Emerging Markets EOS eosinophil EPI epigenetics EPS earnings per share ERoW Established Rest of World ESR1 estrogen receptor alpha ESRD end stage renal disease ETA RA endothelin receptor A antagonist ETARA endothelin receptor A antagonist FDC fixed dose combination FeNO fractional exhaled nitric oxide FL Follicular lymphoma FLAP 5-lipoxygenase activating protein FRα folate receptor alpha FX foreign exchange G7 US, Japan, EU5 GA geographic atrophy GLP-1/glu glucagon-like peptide 1 receptor/glucagon dual peptide agonist GLP-1RA glucagon-like peptide 1 receptor agonist gMG generalised myasthenia gravis GN glomerulonephritis GPC3 Glypican-3 GPRC5D G protein-coupled receptor class C group 5 member D GU genitourinary GYN gynaecologic HbA1c glycated haemoglobin HCC hepatocellular carcinoma HER2 human epidermal growth factor receptor 2 HF heart failure HFrEF heart failure with reduced ejection fraction HK hyperkalaemia HLR high-level results hMPV human metapneumovirus HNSCC head and neck squamous cell carcinoma HR hazard ratio HR+ hormone receptor positive HRR homologous recombination repair HSCT-TMA hematopoietic stem cell transplantation-associated thrombotic microangiopathy i.v. intravenous IBD inflammatory bowel disease ICS inhaled corticosteroid ICU intensive care unit IgAN IgA nephropathy IIT investigated initiated trial iJAK1 inhaled Janus kinase IL-33 interleukin-33 IL-5 interleukin-5 IND investigational new drug IO Immuno-oncology IPF idiopathic pulmonary fibrosis IRA Inflation Reduction Act iTSLP inhaled thymic stromal lymphopoietin ITT intent to treat IVIg intravenous immunoglobulin 1L, 2L, 3L first-, second-, third-line 6MWT 6-minute walk test AAV adeno-associated virus ACE angiotensin-converting enzyme AChR+ acetylcholine receptor-positive ADC antibody conjugate ADsCa albumin-adjusted serum calcium AER annual exacerbation rate AEs adverse effects AGA actional genomic alteration aHUS atypical haemolytic uraemic syndrome AL amyloidosis light-chain amyloidosis AML acute myelogenous leukaemia AMR antibody mediated rejection anti-PCD anti plasma cell dyscrasia AQP4+ aquaporin-4 antibody positive ARB angiotensin receptor blockers ASCO American Society of Clinical Oncology ASI aldosterone synthase inhibitor ASO antisense oligonucleotide ATTR-CM transthyretin amyloid cardiomyopathy ATTR-PN transthyretin amyloid polyneuropathy B-ALL B-cell acute lymphoblastic leukaemia BCMA B-cell maturation antigen BRCA breast cancer gene BTC biliary tract cancer BTKi Bruton's tyrosine kinase C5 complement component 5 CAGR compound adjusted growth rate cAMR chronic antibody-medicated rejection CAR-T chimeric antigen receptor T-cells CD19 Cluster of differentiation 19 CD3 Cluster of differentiation 3 CDK4/6i cyclin-dependent kinase 4/6 inhibitor CER constant exchange rates CI confidence interval CKD chronic kidney disease CLDN 18.2 Claudin-18.2

• 19. 19 Investor Day • 2024 Glossary – 2 of 2 NST neoadjuvant systemic treatment NT-proBNP N-terminal pro-B-type natriuretic peptide NYHA New York Heart Association oGLP1 oral glucagon-like receptor peptide 1 oPCSK9 oral protein convertase subtilisin/kexin type 9 ORR overall response rate oRXFP1 oral relaxin family peptide receptor 1 OS overall survival PALB2m partner and localizer of BRCA2 PARP1 poly(ADP-ribose) polymerase-1 PARPi poly-ADP ribose polymerase inhibitor PD1 programmed cell death protein 1 PD-L1 programmed cell death ligand 1 PFS progression free survival PIK3CA phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit PK/PD pharmacokinetic/pharmacodynamic PLEX plasma exchange PN polyneuropathy PNH paroxysmal nocturnal haemoglobinuria PNH-EVH paroxysmal nocturnal haemoglobinuria with extravascular haemolysis PNPLA3 phospholipase domain-containing protein 3 PP plasmapheresis PSA prostate-specific antigen PSA50 prostate-specific antigen 50 PTEN phosphatase and TENsin homolog deleted on chromosome 10 PYR peak year revenue Q2W every 2 weeks Q4W every 4 weeks Q8W every 8 weeks QCS quantitative continuous scoring QoQ quarter on quarter R&D research and development R&I Respiratory and Immunology r/r relapsed/refractory RA rheumatoid arthritis RAGE receptor for advanced glycation end products RC radioconjugates RP2D recommended Phase II dose RSV respiratory syncytial virus s. asthma severe asthma s.c. subcutaneous SABA short acting beta agonist SBP systolic blood pressure SBRT stereotactic brain radiotherapy SC subcutaneous SG&A Selling, General and Administrative SGLT2i sodium/glucose cotransporter 2 inhibitor sK serum potassium SLE systemic lupus erythematosus SoC standard of care ST2 suppression of tumorigenicity 2 Stg. I/II/III Stage I/II/III Stg. III u/r NSCLC Stage III unresectable non-small cell lung cancer T2D type-2 diabetes T8 US, China, Japan, EU5 TCE T-cell engager tCO2e tonnes of carbon dioxide equivalent TCR T-cell receptor TDR tumour drivers and resistance TIGIT T-cell immunoreceptor with immunoglobulin and ITIM domains TIM-3 T-cell immunoglobulin and mucin domain-containing protein TKI tyrosine kinase inhibitor TNBC triple negative breast cancer TP53 tumour protein 53 Treg Regulatory T-cell TROP2 trophoblast cell surface antigen 2 TTR transthyretin u/r HTN uncontrolled or treatment resistant hypertension UACR urinary albumin/creatinine ratio ULN upper limit of normal V&I Vaccines and Immune Therapies VLP virus-like particle K+ potassium KCCQ Kansas City Cardiomyopathy Questionnaire LA amylin long-acting amylin LABA long-acting beta 2-agonists LAMA long-acting muscarinic antagonists LCM life cycle management LDL-C low-density lipoprotein cholesterol LN lupus nephritis LoE loss of exclusivity LS-SCLC limited stage small-cell lung cancer LV left ventricular mAb monoclonal antibody MASH metabolic dysfunction-associated steatohepatitis, also known as nonalcoholic steatohepatitis (NASH) MASLD metabolic dysfunction-associated steatotic liver disease mBC metastatic breast cancer MCL mantle cell lymphoma mDOR median duration of response mg/dL milligrams per decilitre MGFA Myasthenia Gravis Foundation of America mHSPC metastatic hormone sensitive prostate cancer mL millilitre MM multiple myeloma MoA mechanism of action MPO myeloperoxidase MRA mineralocorticoid receptor antagonist MRM mineralocorticoid receptor modulator n/m not material NBRx new-to-brand prescription Neo-adj neoadjuvant NF1-PN neurofibromatosis type 1-plexiform neurofibromas ngSERD next-generation oral selective estrogen receptor degrader NHA novel hormone agent NME new molecular entity NMOSD neuromyelitis optica spectrum disorder NP nasal polyps NRDL national reimbursement drug list NSCLC non-small cell lung cancer